A detailed history of Black Rock Inc. transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 3,621,949 shares of ALDX stock, worth $17.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,621,949
Previous 3,310,787 9.4%
Holding current value
$17.7 Million
Previous $10.8 Million 10.73%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$3.25 - $4.72 $1.01 Million - $1.47 Million
311,162 Added 9.4%
3,621,949 $12 Million
Q1 2024

May 10, 2024

SELL
$2.77 - $4.22 $332,363 - $506,345
-119,987 Reduced 3.5%
3,310,787 $10.8 Million
Q4 2023

Feb 13, 2024

BUY
$1.47 - $6.06 $87,673 - $361,430
59,642 Added 1.77%
3,430,774 $12 Million
Q3 2023

Nov 13, 2023

BUY
$6.11 - $8.16 $859,786 - $1.15 Million
140,718 Added 4.36%
3,371,132 $22.5 Million
Q2 2023

Aug 11, 2023

BUY
$7.11 - $11.89 $16 Million - $26.7 Million
2,245,432 Added 227.97%
3,230,414 $27.1 Million
Q1 2023

May 12, 2023

BUY
$5.77 - $9.93 $72,390 - $124,581
12,546 Added 1.29%
984,982 $9.78 Million
Q4 2022

Feb 13, 2023

BUY
$5.08 - $7.09 $11,938 - $16,661
2,350 Added 0.24%
972,436 $6.77 Million
Q3 2022

Nov 14, 2022

SELL
$3.8 - $7.74 $18,471 - $37,624
-4,861 Reduced 0.5%
970,086 $5.18 Million
Q2 2022

Aug 12, 2022

SELL
$2.43 - $4.85 $5.46 Million - $10.9 Million
-2,245,564 Reduced 69.73%
974,947 $3.89 Million
Q1 2022

May 12, 2022

SELL
$3.25 - $5.17 $26,975 - $42,911
-8,300 Reduced 0.26%
3,220,511 $14.3 Million
Q4 2021

Feb 10, 2022

SELL
$3.5 - $9.63 $122,958 - $338,311
-35,131 Reduced 1.08%
3,228,811 $12.9 Million
Q3 2021

Nov 09, 2021

SELL
$7.94 - $11.31 $94,025 - $133,933
-11,842 Reduced 0.36%
3,263,942 $28.7 Million
Q2 2021

Aug 11, 2021

BUY
$10.44 - $14.85 $34.2 Million - $48.6 Million
3,275,784 New
3,275,784 $37.1 Million

Others Institutions Holding ALDX

About Aldeyra Therapeutics, Inc.


  • Ticker ALDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,323,100
  • Market Cap $285M
  • Description
  • Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...
More about ALDX
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.